卡培他滨-话题@MedSci

#卡培他滨#

72篇内容 | 3110人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1293510, encodeId=5fe41293510c3, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=Lancet Oncol:表阿霉素/顺铂/卡培他滨新辅助治疗食管腺癌并不优于标准治疗, objectType=article, longId=108311, objectId=a8c210831193, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8c210831193, replyNumber=0, likeNumber=61, createdTime=2017-08-11, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8c210831193, moduleTitle=Lancet Oncol:表阿霉素/顺铂/卡培他滨新辅助治疗食管腺癌并不优于标准治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8c210831193)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293509, encodeId=dc0012935098e, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=Lancet oncol：食管腺癌术前行新辅助化疗顺铂联合氟尿嘧啶与表柔比星、顺铂联合卡培他滨的疗效对比。, objectType=article, longId=107807, objectId=d5be10e807c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5be10e807c3, replyNumber=0, likeNumber=50, createdTime=2017-08-06, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5be10e807c3, moduleTitle=Lancet oncol：食管腺癌术前行新辅助化疗顺铂联合氟尿嘧啶与表柔比星、顺铂联合卡培他滨的疗效对比。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5be10e807c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293508, encodeId=141512935087a, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=JAMA Oncology：维生素B6不能预防卡培他滨引起的手足综合征, objectType=article, longId=105570, objectId=eafd1055e000, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eafd1055e000, replyNumber=0, likeNumber=74, createdTime=2017-07-16, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eafd1055e000, moduleTitle=JAMA Oncology：维生素B6不能预防卡培他滨引起的手足综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eafd1055e000)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293507, encodeId=4234129350eb3, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=SCI REP：卡培他滨和紫杉醇治疗转移性胰腺癌患者总体生存率的生化和遗传预测因子！, objectType=article, longId=105032, objectId=80fb105032bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80fb105032bc, replyNumber=0, likeNumber=48, createdTime=2017-07-10, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80fb105032bc, moduleTitle=SCI REP：卡培他滨和紫杉醇治疗转移性胰腺癌患者总体生存率的生化和遗传预测因子！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80fb105032bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293506, encodeId=3c18129350600, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=JAMA Oncology：卡培他滨联合多西他赛、表柔比星以及环磷酰胺进行早期乳腺癌新辅助治疗, objectType=article, longId=104744, objectId=68dd104e44bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68dd104e44bd, replyNumber=0, likeNumber=87, createdTime=2017-07-07, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68dd104e44bd, moduleTitle=JAMA Oncology：卡培他滨联合多西他赛、表柔比星以及环磷酰胺进行早期乳腺癌新辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68dd104e44bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293505, encodeId=48ca12935050a, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=JAMA Oncology：晚期胃食管交界处肿瘤卡培他滨疗效与质子泵抑制剂之间的关系, objectType=article, longId=104742, objectId=5769104e42a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5769104e42a9, replyNumber=0, likeNumber=58, createdTime=2017-07-07, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5769104e42a9, moduleTitle=JAMA Oncology：晚期胃食管交界处肿瘤卡培他滨疗效与质子泵抑制剂之间的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5769104e42a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293504, encodeId=a89512935044e, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=New Engl J Med ：乳腺癌患者福音:卡培他滨对于棘手的乳腺癌效果神奇！, objectType=article, longId=100669, objectId=450210066956, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=450210066956, replyNumber=0, likeNumber=61, createdTime=2017-06-05, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=450210066956, moduleTitle=New Engl J Med ：乳腺癌患者福音:卡培他滨对于棘手的乳腺癌效果神奇！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=450210066956)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293503, encodeId=c77a12935035a, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=NEJM：卡培他滨用于HER2阴性侵袭性乳腺癌, objectType=article, longId=100383, objectId=5ff6100383d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ff6100383d7, replyNumber=0, likeNumber=66, createdTime=2017-06-03, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ff6100383d7, moduleTitle=NEJM：卡培他滨用于HER2阴性侵袭性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ff6100383d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293502, encodeId=292d129350239, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=Lancet：胰腺癌手术切除的患者：辅助吉西他滨+卡培他滨vs吉西他滨单药, objectType=article, longId=97105, objectId=a68e9e10542, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a68e9e10542, replyNumber=0, likeNumber=76, createdTime=2017-04-27, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a68e9e10542, moduleTitle=Lancet：胰腺癌手术切除的患者：辅助吉西他滨+卡培他滨vs吉西他滨单药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a68e9e10542)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293501, encodeId=1a961293501a3, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=The Lancet Gastroenterology & Hepatology：veliparib联合卡培他滨加放疗治疗晚期直肠癌的安全性, objectType=article, longId=93776, objectId=2b1b93e7645, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b1b93e7645, replyNumber=0, likeNumber=62, createdTime=2017-03-30, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b1b93e7645, moduleTitle=The Lancet Gastroenterology & Hepatology：veliparib联合卡培他滨加放疗治疗晚期直肠癌的安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b1b93e7645)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293500, encodeId=b615129350006, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=LANCET：吉西他滨+卡培他滨vs.吉西他滨单一给药在胰腺癌切除术后的疗效, objectType=article, longId=88165, objectId=e27d881657b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e27d881657b, replyNumber=0, likeNumber=50, createdTime=2017-02-01, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e27d881657b, moduleTitle=LANCET：吉西他滨+卡培他滨vs.吉西他滨单一给药在胰腺癌切除术后的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e27d881657b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293499, encodeId=acba1293499a2, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=Lancet Oncol：HER2-乳癌患者：贝伐单抗+卡培他滨 vs 贝伐单抗+紫杉醇(TURANDOT), objectType=article, longId=76930, objectId=9a94e693000, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a94e693000, replyNumber=0, likeNumber=30, createdTime=2016-09-09, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a94e693000, moduleTitle=Lancet Oncol：HER2-乳癌患者：贝伐单抗+卡培他滨 vs 贝伐单抗+紫杉醇(TURANDOT), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a94e693000)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293498, encodeId=5c4f129349870, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=服用卡培他滨，你可能不了解的几个细节, objectType=article, longId=71248, objectId=d451e1248ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d451e1248ed, replyNumber=0, likeNumber=47, createdTime=2016-06-21, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d451e1248ed, moduleTitle=服用卡培他滨，你可能不了解的几个细节, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d451e1248ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293497, encodeId=1859129349e79, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=JCO：拉帕替尼联用卡培他滨和奥沙利铂并不延长胃癌患者总生存时间, objectType=article, longId=60099, objectId=b5e3600995e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5e3600995e, replyNumber=0, likeNumber=48, createdTime=2015-12-05, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5e3600995e, moduleTitle=JCO：拉帕替尼联用卡培他滨和奥沙利铂并不延长胃癌患者总生存时间, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5e3600995e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293496, encodeId=00f81293496b5, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=招募患者：马来酸吡咯替尼片联合卡培他滨对比拉帕替尼联合卡培他滨治疗HER2表达阳性转移性乳腺癌的I/II期临床研究, objectType=article, longId=56015, objectId=17c9560153c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17c9560153c, replyNumber=0, likeNumber=60, createdTime=2015-09-11, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17c9560153c, moduleTitle=招募患者：马来酸吡咯替尼片联合卡培他滨对比拉帕替尼联合卡培他滨治疗HER2表达阳性转移性乳腺癌的I/II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17c9560153c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293495, encodeId=0960129349569, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=ASCO 2015：化疗后卡培他滨单药维持对mCRC的疗效, objectType=article, longId=51425, objectId=80e15142500, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80e15142500, replyNumber=0, likeNumber=0, createdTime=2015-05-31, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80e15142500, moduleTitle=ASCO 2015：化疗后卡培他滨单药维持对mCRC的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80e15142500)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293494, encodeId=7c9a1293494ca, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=Lancet：贝伐与卡培他滨两药联用维持治疗结直肠癌使总生存期获益, objectType=article, longId=49234, objectId=7bca4923406, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bca4923406, replyNumber=0, likeNumber=52, createdTime=2015-04-12, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bca4923406, moduleTitle=Lancet：贝伐与卡培他滨两药联用维持治疗结直肠癌使总生存期获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bca4923406)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293493, encodeId=14a7129349301, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=Lancet：卡培他滨联合贝伐单抗治疗转移性结肠癌效果良好, objectType=article, longId=49106, objectId=cbf949106b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbf949106b5, replyNumber=0, likeNumber=66, createdTime=2015-04-10, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbf949106b5, moduleTitle=Lancet：卡培他滨联合贝伐单抗治疗转移性结肠癌效果良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbf949106b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293492, encodeId=2aa212934922c, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=Oncologist：卡培他滨+舒尼替尼治疗对乳腺癌患者脑转移无益, objectType=article, longId=42397, objectId=68a04239e28, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68a04239e28, replyNumber=0, likeNumber=81, createdTime=2014-11-12, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68a04239e28, moduleTitle=Oncologist：卡培他滨+舒尼替尼治疗对乳腺癌患者脑转移无益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68a04239e28)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293491, encodeId=8675129349189, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=Lancet Oncol：S-1联合奥沙利铂与卡培他滨联合奥沙利铂一线治疗转移性结直肠癌患者：一项III期临床试验的全新结果, objectType=article, longId=37049, objectId=a8b93e049a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8b93e049a1, replyNumber=0, likeNumber=0, createdTime=2014-06-27, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8b93e049a1, moduleTitle=Lancet Oncol：S-1联合奥沙利铂与卡培他滨联合奥沙利铂一线治疗转移性结直肠癌患者：一项III期临床试验的全新结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8b93e049a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

卡培他滨

2020-05-29

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

Lancet Oncol:表阿霉素/顺铂/卡培他滨新辅助治疗食管腺癌并不优于标准治疗

2017-08-11

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

Lancet oncol：食管腺癌术前行新辅助化疗顺铂联合氟尿嘧啶与表柔比星、顺铂联合卡培他滨的疗效对比。

2017-08-06

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

JAMA Oncology：维生素B6不能预防卡培他滨引起的手足综合征

2017-07-16

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

SCI REP：卡培他滨和紫杉醇治疗转移性胰腺癌患者总体生存率的生化和遗传预测因子！

2017-07-10

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

JAMA Oncology：卡培他滨联合多西他赛、表柔比星以及环磷酰胺进行早期乳腺癌新辅助治疗

2017-07-07

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

JAMA Oncology：晚期胃食管交界处肿瘤卡培他滨疗效与质子泵抑制剂之间的关系

2017-07-07

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

New Engl J Med ：乳腺癌患者福音:卡培他滨对于棘手的乳腺癌效果神奇！

2017-06-05

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

NEJM：卡培他滨用于HER2阴性侵袭性乳腺癌

2017-06-03

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

Lancet：胰腺癌手术切除的患者：辅助吉西他滨+卡培他滨vs吉西他滨单药

2017-04-27

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

The Lancet Gastroenterology & Hepatology：veliparib联合卡培他滨加放疗治疗晚期直肠癌的安全性

2017-03-30

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

LANCET：吉西他滨+卡培他滨vs.吉西他滨单一给药在胰腺癌切除术后的疗效

2017-02-01

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

Lancet Oncol：HER2-乳癌患者：贝伐单抗+卡培他滨 vs 贝伐单抗+紫杉醇(TURANDOT)

2016-09-09

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

服用卡培他滨，你可能不了解的几个细节

2016-06-21

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

JCO：拉帕替尼联用卡培他滨和奥沙利铂并不延长胃癌患者总生存时间

2015-12-05

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

招募患者：马来酸吡咯替尼片联合卡培他滨对比拉帕替尼联合卡培他滨治疗HER2表达阳性转移性乳腺癌的I/II期临床研究

2015-09-11

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

ASCO 2015：化疗后卡培他滨单药维持对mCRC的疗效

2015-05-31

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

Lancet：贝伐与卡培他滨两药联用维持治疗结直肠癌使总生存期获益

2015-04-12

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

Lancet：卡培他滨联合贝伐单抗治疗转移性结肠癌效果良好

2015-04-10

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

Oncologist：卡培他滨+舒尼替尼治疗对乳腺癌患者脑转移无益

2014-11-12

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

Lancet Oncol：S-1联合奥沙利铂与卡培他滨联合奥沙利铂一线治疗转移性结直肠癌患者：一项III期临床试验的全新结果

2014-06-27

科室
- - 订阅+
  - 更多科室
工具
服务